Vulvar Atrophy
1
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Regen LabSwitzerland - Le Mont-sur-Lausanne
1 programCellular Matrix BCT-HA KitN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Daré BioscienceTamoxifen
Regen LabCellular Matrix BCT-HA Kit
Clinical Trials (2)
Total enrollment: 37 patients across 2 trials
Study of Intravaginal Tamoxifen in PostMenopausal Women With VVA
Start: Nov 2021Est. completion: Mar 202317 patients
Phase 1/2Completed
Autologous Platelet Concentrate Combined to Hyaluronic Acid Obtained With Cellular Matrix® BCT-HA Kit and Vulvovaginal Dryness
Start: Mar 2016Est. completion: Dec 201720 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.